77,901 Pro-Dex, Inc. $PDEX Shares Acquired by Global Retirement Partners LLC

Global Retirement Partners LLC raised its stake in shares of Pro-Dex, Inc. (NASDAQ:PDEX – Free Report) by 7,790.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 78,901 shares of the medical instruments supplier’s stock after buying an additional 77,901 shares during the period. Global Retirement Partners LLC owned approximately 2.47% of Pro-Dex worth $5,444,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PDEX. Punch & Associates Investment Management Inc. lifted its stake in shares of Pro-Dex by 2.9% in the 1st quarter. Punch & Associates Investment Management Inc. now owns 61,735 shares of the medical instruments supplier’s stock worth $3,032,000 after acquiring an additional 1,735 shares during the period. Pekin Hardy Strauss Inc. boosted its holdings in shares of Pro-Dex by 38.2% in the third quarter. Pekin Hardy Strauss Inc. now owns 22,800 shares of the medical instruments supplier’s stock valued at $1,573,000 after acquiring an additional 6,300 shares in the last quarter. Ellsworth Advisors LLC acquired a new position in shares of Pro-Dex during the third quarter valued at approximately $1,166,000. Russell Investments Group Ltd. increased its stake in shares of Pro-Dex by 1,443.6% during the third quarter. Russell Investments Group Ltd. now owns 11,191 shares of the medical instruments supplier’s stock valued at $772,000 after acquiring an additional 10,466 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in Pro-Dex in the second quarter worth approximately $678,000. 15.28% of the stock is currently owned by institutional investors.

Pro-Dex Trading Up 3.2%

Shares of NASDAQ:PDEX opened at $63.94 on Thursday. The stock has a market capitalization of $204.61 million, a price-to-earnings ratio of 16.97 and a beta of 0.12. Pro-Dex, Inc. has a 1-year low of $28.81 and a 1-year high of $77.00. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.49 and a current ratio of 4.19. The company has a 50 day moving average price of $64.84 and a 200 day moving average price of $58.03.

Pro-Dex (NASDAQ:PDEX – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The medical instruments supplier reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. Pro-Dex had a return on equity of 26.18% and a net margin of 15.12%. The company had revenue of $20.56 million for the quarter, compared to analysts’ expectations of $20.40 million. On average, research analysts anticipate that Pro-Dex, Inc. will post 3.09 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Weiss Ratings raised Pro-Dex from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, November 10th. Zacks Research downgraded Pro-Dex from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 9th. Finally, Ascendiant Capital Markets upped their price objective on Pro-Dex from $74.00 to $80.00 and gave the company a “buy” rating in a report on Monday. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $80.00.

Read Our Latest Analysis on Pro-Dex

Insiders Place Their Bets

In other news, CEO Kirk Richard Lee Van, Jr. sold 19,235 shares of the company’s stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $60.58, for a total transaction of $1,165,256.30. Following the completion of the sale, the chief executive officer directly owned 79,993 shares of the company’s stock, valued at $4,845,975.94. This represents a 19.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Alisha Charlton sold 2,300 shares of the stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $61.30, for a total value of $140,990.00. Following the completion of the transaction, the chief financial officer owned 21,870 shares of the company’s stock, valued at $1,340,631. This trade represents a 9.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 22,300 shares of company stock worth $1,351,657 over the last 90 days. Insiders own 48.00% of the company’s stock.

Pro-Dex Profile

(Free Report)

Pro-Dex, Inc. designs, develops and manufactures powered surgical instruments and related accessories, with a focus on devices used in orthopedic procedures. Its products include surgical handpieces and drivers, along with the components and systems that support their operation. The company also provides engineering, product development and manufacturing services to medical device companies. Its work can span the product lifecycle, from design and prototyping to production and servicing. Founded in 1978, Pro-Dex is headquartered in Irvine, California, and serves customers in the United States and international markets.

Further Reading

Want to see what other hedge funds are holding PDEX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pro-Dex, Inc. (NASDAQ:PDEX – Free Report).

Institutional Ownership by Quarter for Pro-Dex (NASDAQ:PDEX)

Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.